{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:51:48Z","timestamp":1792792308356,"version":"4.5.0"},"reference-count":122,"publisher":"Informa UK Limited","issue":"4","funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["22377013"],"award-info":[{"award-number":["22377013"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011198","name":"the State Key Laboratory of Drug Research","doi-asserted-by":"crossref","award":["SKLDR-2023-KF-07"],"award-info":[{"award-number":["SKLDR-2023-KF-07"]}],"id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"crossref"}]},{"name":"the Science and Technology Commission of Shanghai Municipality","award":["YDZX20233100004032"],"award-info":[{"award-number":["YDZX20233100004032"]}],"id":[{"id":"https:\/\/ror.org\/03kt66j61","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Major Program of Guangzhou National Laboratory","award":["GZNL2023A02012"],"award-info":[{"award-number":["GZNL2023A02012"]}],"id":[{"id":"https:\/\/ror.org\/03ybmxt82","id-type":"ROR","asserted-by":"crossref"}]},{"name":"High-level Innovative Research Institute","award":["2021B0909050003"],"award-info":[{"award-number":["2021B0909050003"]}]}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2025,4,3]]},"DOI":"10.1080\/13543776.2025.2463150","type":"journal-article","created":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T07:03:26Z","timestamp":1738911806000},"page":"371-386","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["A patent review of BRD4 inhibitors (2020\u2013present)"],"prefix":"10.1080","volume":"35","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-8275-7378","authenticated-orcid":false,"given":"Yanfang","family":"Chen","sequence":"first","affiliation":[{"name":"Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, the Key Laboratory of Innate Immune Biology of Fujian Province, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-3924-3338","authenticated-orcid":false,"given":"Huanmin","family":"Zhou","sequence":"additional","affiliation":[{"name":"Fujian Medical University","place":["Fuzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-5329-9314","authenticated-orcid":false,"given":"Jiamin","family":"Yu","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Chinese Academy of Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-8844-273X","authenticated-orcid":false,"given":"Jing","family":"Gao","sequence":"additional","affiliation":[{"name":"Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, the Key Laboratory of Innate Immune Biology of Fujian Province, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1809-672X","authenticated-orcid":false,"given":"Shengyu","family":"Xue","sequence":"additional","affiliation":[{"name":"Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Chinese Academy of Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7923-0527","authenticated-orcid":false,"given":"Hong","family":"Ding","sequence":"additional","affiliation":[{"name":"Chinese Academy of Sciences","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0840-6553","authenticated-orcid":false,"given":"Hua","family":"Lin","sequence":"additional","affiliation":[{"name":"Key Laboratory of Microbial Pathogenesis and Interventions of Fujian Province University, the Key Laboratory of Innate Immune Biology of Fujian Province, Biomedical Research Center of South China, College of Life Sciences, Fujian Normal University, Fuzhou, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3864-8382","authenticated-orcid":false,"given":"Cheng","family":"Luo","sequence":"additional","affiliation":[{"name":"Fujian Medical University","place":["Fuzhou, China"]},{"name":"Nanjing University of Chinese Medicine","place":["Nanjing, China"]},{"name":"Chinese Academy of Sciences","place":["Shanghai, China"]},{"name":"University of Chinese Academy of Sciences","place":["Hangzhou, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2025,2,14]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-17-0605"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2022.102148"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2012.02.013"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature08397"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2014.05.016"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc3256"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1997.5000"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.1175371"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1038\/20974"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm200108t"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature12147"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.06.029"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2005.06.027"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1101\/gad.221895.113"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/20.10.2603"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.3551"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.2174\/1389557516666160611014130"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2020.1702645"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-14-0305"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.4131"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108304"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90499-g"},{"key":"e_1_3_5_25_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9440(10)63049-0"},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.V126.23.1491.1491"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.1572"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-13-0925"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6275"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.733"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2013.338"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaci.2018.09.029"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.179"},{"key":"e_1_3_5_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature09589"},{"key":"e_1_3_5_35_1","doi-asserted-by":"publisher","DOI":"10.1038\/nature10334"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/onc.2013.126"},{"key":"e_1_3_5_37_1","doi-asserted-by":"publisher","DOI":"10.1038\/srep24100"},{"key":"e_1_3_5_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy048"},{"key":"e_1_3_5_39_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5b01882"},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/leu.2016.355"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2015.05.009"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2013-1126"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbpa.2019.02.022"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41568-021-00365-x"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-16-2622"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aab1433"},{"key":"e_1_3_5_47_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-023-00736-3"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1021\/acschembio.5b00216"},{"key":"e_1_3_5_49_1","unstructured":"Garrick S Slavko R Luigi S et al inventors. Compounds active towards Bromodomains patent WO2023205251. 2023."},{"key":"e_1_3_5_50_1","unstructured":"Martin M Zhifeng Y Ramkumar M et al inventors. Bromodomain and Extra-Terminal (Bet) Subfamily Bromodomain 1 (Bd1) selective inhibitors and methods using same patent WO2023196455. 2023."},{"key":"e_1_3_5_51_1","unstructured":"Bing X Jingkang S Zehong M et al inventors. BRD4 inhibitor as well as a preparative method and use thereof patent CN113121528. 2020."},{"key":"e_1_3_5_52_1","unstructured":"Haiquan F Mingming C Guiqun Y et al inventors. Tricyclic Compounds patent WO2020001152. 2020."},{"key":"e_1_3_5_53_1","unstructured":"Ying H Dapeng L Huajun L et al inventors. Tricyclic Compounds as Anticancer Agents patent WO2022156757. 2022."},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2023.106720"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.6b01816"},{"key":"e_1_3_5_56_1","unstructured":"Xavier M Jean-Claude CSG Yves BSC et al inventors. Xanthine derivative inhibitors of BET proteins patent US11225481. 2022."},{"key":"e_1_3_5_57_1","unstructured":"St\u00e9phane B S\u00e9bastien C Yves C et al inventors. Xanthine derivatives and uses thereof as inhibitors of bromodomains of BET proteins patent US11180510. 2023."},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.2c00300"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd4670"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1521738113"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1039\/c8md00198g"},{"key":"e_1_3_5_62_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaz8455"},{"key":"e_1_3_5_63_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.phrs.2021.105804"},{"key":"e_1_3_5_64_1","unstructured":"Filippakopoulos P Knapp S inventors. Targeting bromodomains: epigenetic readers of lysine acetylation patent EP3174868. 2021."},{"key":"e_1_3_5_65_1","unstructured":"Hay D Fedorov O Filippakopoulos P et al inventors. The design and synthesis of 5- and 6-isoxazolylbenzimidazoles as selective inhibitors of the BET bromodomains patent EP3033335. 2020."},{"key":"e_1_3_5_66_1","unstructured":"dL R Zheng M Berlin J et al inventors. Bicyclic and tricyclic heterocycle derivatives as histamine H3 receptor antagonists for the treatment of obesity patent EP341696. 2021."},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-01-478420"},{"key":"e_1_3_5_68_1","unstructured":"Haitao H Jia Z Zhiqing L. inventors. Small molecule BRD4 modulators for HIV epigenetic regulation patent US10975059. 2021."},{"key":"e_1_3_5_69_1","unstructured":"Lin X Meiyu G Leping L et al inventors. Compound Having Brd4 inhibitory activity preparation method therefor and use thereof patent EP4043462. 2022."},{"key":"e_1_3_5_70_1","unstructured":"Christopher W Mark B inventors. Pyrrolopyridone derivatives useful in the treatment of cancer patent WO2023275542. 2023."},{"key":"e_1_3_5_71_1","unstructured":"Woodland CA Bell M inventors. Pyridone-containing compounds as bromodomain protein inhibitors patent WO2022090699. 2022."},{"key":"e_1_3_5_72_1","unstructured":"Andrew W Mark B. inventors.Compounds Comprising N-Methyl-2-Pyridone and pharmaceutically acceptable salts patent US20220204500. 2022."},{"key":"e_1_3_5_73_1","unstructured":"Huixin W Jianfeng P Jingui M. Inventors. pyrrole amidopyridone compound preparation method therefor and use thereof patent EP3967690. 2022."},{"key":"e_1_3_5_74_1","unstructured":"Pham SM Jayakanth K Sarvajit C et al inventor. Heterocyclic compounds as bet inhibitors patent WO2021003310. 2021."},{"key":"e_1_3_5_75_1","unstructured":"Pham SM Jayakanth K Chris P et al inventors. Heterocyclic Compounds as Bet Inhibitors patent WO2021222466. 2021."},{"key":"e_1_3_5_76_1","unstructured":"Kip GR Jake SP Robert SW et al. inventors. Tetrahydroquinoline-based bromodomain inhibitors patent US11028051. 2020."},{"key":"e_1_3_5_77_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2013.12.039"},{"key":"e_1_3_5_78_1","unstructured":"Bair Kenneth WH Kauffman Goss S Kayser-Bricker Katherine J et al inventors. Benzopiperazine compositions as BET bromodomain inhibitors patent US11084831. 2021."},{"key":"e_1_3_5_79_1","unstructured":"Ca P Sr B P MJT et al. inventors. Tricyclic heterocycles as bet protein inhibitors patent US20200131195. 2020."},{"key":"e_1_3_5_80_1","unstructured":"Hao L Long BJ Rui RH et al. inventors. Compound Having benzo seven-membered ring structure preparation method therefor and use thereof patent EP3919479. 2024."},{"key":"e_1_3_5_81_1","unstructured":"Mark B William FD Andrew WC et al inventors. Pyrroles and Imidazoles as bet protein inhibitors patent WO2024018423. 2024."},{"key":"e_1_3_5_82_1","unstructured":"Andrew S Mehmet K Michael B. inventors.Anticancer compounds patent WO2022261204. 2022."},{"key":"e_1_3_5_83_1","unstructured":"Sarvajit PSMC Jiyun KJC Kumar NA et al. inventors. Substituted 1 6-dihydropyridinones and 1 2-dihydroisoquinolinones as bet inhibitors patent US 11192900. 2021."},{"key":"e_1_3_5_84_1","unstructured":"Jilkova M Anouk GJE Carlo P et al. inventors. Tetrahydroquinoline (Thq) Coumpounds patent WO2022248475. 2021."},{"key":"e_1_3_5_85_1","unstructured":"Chunli S Yuchuan Z Ting W et al. inventors. Compounds having both effects of bet bromodomain protein inhibition and Pd-L1 gene regulation patent EP3936507. 2022."},{"key":"e_1_3_5_86_1","unstructured":"Chunli S Chengde W Yong L et al. inventors. Thienodiazepine derivatives and application thereof patent EP3686204. 2022."},{"key":"e_1_3_5_87_1","unstructured":"Lei F Kexin X Ke C et al. inventors. Brd4 Inhibitor patent US20200255450. 2020."},{"key":"e_1_3_5_88_1","unstructured":"Ls B Michael K. inventors. Bromodomain Inhibitors patent EP3212654. 2020."},{"key":"e_1_3_5_89_1","unstructured":"Kempen Herman FA. inventor.Preparation of condensed triazepine derivatives and their use as bet inhibitors patent US20200231598. 2020."},{"key":"e_1_3_5_90_1","unstructured":"Shaomeng W Jiantao H Fuming X. inventors. Fused 1 4-diazepines as BET bromodomain inhibitors patent US11046709. 2021."},{"key":"e_1_3_5_91_1","unstructured":"Bradner James E Jun Q Minoru T et al. inventors. Cyano Thienotriazolodiazepines and uses thereof patent US20210206779. 2020."},{"key":"e_1_3_5_92_1","unstructured":"Michael B Juan B Amogh B et al. inventors. Bromodomain Inhibitors patent US20200071332. 2020."},{"key":"e_1_3_5_93_1","unstructured":"Mehrnaz P Guillaume J Shawn CSBMJ et al. inventorsSubstituted benzimidazoles their preparation and their use as pharmaceuticals patent US11365186. 2021."},{"key":"e_1_3_5_94_1","unstructured":"Shuang L Frederick QJ Cordell DB et al. inventorsSubstituted bicyclic compounds as bromodomain inhibitors patent US11026926. 2021."},{"key":"e_1_3_5_95_1","unstructured":"Combs Andrew P Maduskuie Jr Thomas P Falahatpisheh N. inventor.1H-pyrrolo[2 3-c]pyridin-7(6H)-ones and pyrazolo[3 4-c]pyridin-7(6H)-ones as inhibitors of BET proteins patent US11059821. 2020."},{"key":"e_1_3_5_96_1","unstructured":"Li Jijun ZY Yeliu W. Shang Xianxing Wang Huting inventor Sulfoximine compound as bromodomain protein inhibitor and pharmaceutical composition and medical use thereof patent EP3828183. 2022."},{"key":"e_1_3_5_97_1","unstructured":"Lei F Fei W Xiaoquan W et al. inventors. Brd4 Inhibitor preparation method and use thereof patent EP3831828. 2021."},{"key":"e_1_3_5_98_1","unstructured":"Le W John K Keith F et al inventors. Bromodomain Inhibitors patent US20230158039. 2023."},{"key":"e_1_3_5_99_1","unstructured":"Yan X Xiaofeng X Jiabing W et al. inventors. Compound functioning as bromodomain protein inhibitor and composition patent US11466034. 2022."},{"key":"e_1_3_5_100_1","unstructured":"Mark S Mathew B Augelli-Szafran C et al. inventors. Development of Potential Antidotes for Arsenicals patent WO2023133354. 2023."},{"key":"e_1_3_5_101_1","unstructured":"James D Haisheng W Lixin S et al inventors. Tricyclic heterocycles as BET protein inhibitors patent US11091484. 2021."},{"key":"e_1_3_5_102_1","unstructured":"Chunli S Yong L Chengde W et al. inventors. 5-Membered heteroaromatic pyridone compounds and application thereof patent WO2022033542. 2020."},{"key":"e_1_3_5_103_1","unstructured":"Bing Z Cheng L Zizhou L et al. inventors. Bromodomain inhibitor compound and use thereof patent US11427593. 2022."},{"key":"e_1_3_5_104_1","unstructured":"Nenghui W. inventor. Carboline derivative serving as bromodomain inhibitor patent EP3406612. 2021."},{"key":"e_1_3_5_105_1","unstructured":"Qchlh M. inventor. Tricyclic compounds as anticancer agents patent US10683290. 2020."},{"key":"e_1_3_5_106_1","unstructured":"Norris Derek DG Ashvinikumar G Quesnelle C inventor. Tricyclic Compound as Anticancer Agents patent EP3466949. 2020."},{"key":"e_1_3_5_107_1","unstructured":"Sch\u00f6nbrunn Ernst LN Lawrence H inventor. BRD4-kinase inhibitors as cancer therapeutics patent US10738016. 2020."},{"key":"e_1_3_5_108_1","unstructured":"Selnjlhrr G inventor. Potent dual BRD4-kinase inhibitors as cancer therapeutics patent US10526291. 2020."},{"key":"e_1_3_5_109_1","unstructured":"Ch\u00f6nbrunn Ernst LN inventor. Brd4-Jak2 Inhibitors patent US20210355088. 2021."},{"key":"e_1_3_5_110_1","unstructured":"Bradner James E Jun Q Minoru T inventors. Diaminopyrimidine benzenesulfone derivatives and uses thereof patent US10730860. 2020."},{"key":"e_1_3_5_111_1","unstructured":"Ernst Lnjlhr S inventor. Brd4-Jak2 Inhibitors patent WO2020051572.2020."},{"key":"e_1_3_5_112_1","unstructured":"Jiang Y Yuanwei C inventors. Ar and bet dual inhibitor and use thereof. patent WO2020063968. 2020."},{"key":"e_1_3_5_113_1","unstructured":"Wu D Haibin L Dekun Q et al. inventors. Aromatic Amine compound and use thereof in preparation of Ar and Brd4 dual inhibitors and regulators patent WO2020200209. 2020."},{"key":"e_1_3_5_114_1","unstructured":"Amogh B inventor. Bromodomain Inhibitors patent US20200148703. 2020."},{"key":"e_1_3_5_115_1","unstructured":"Keiko M Saeki Kazunori TT Masataka F et al. inventors. Antitumor Agent and Bromodomain Inhibitor patent EP3563851. 2021."},{"key":"e_1_3_5_116_1","unstructured":"Guillaume Bmjs J Albert Jeffrey S Andrew G. inventors. Aryl-substituted dihydroquinolinones their preparation and their use as pharmaceuticals patent EP3334717. 2020."},{"key":"e_1_3_5_117_1","unstructured":"Bailey Simon LG inventor. Propargyl compounds and pharmaceutical compositions that modulate Brd4 patent WO2023196512. 2023."},{"key":"e_1_3_5_118_1","unstructured":"Kwangho L Gildon C Imran A et al. inventors. [1 2 4]Triazolo4 3-a]quinoxaline derivative method for preparing same and pharmaceutical composition for preventing or treating BET protein-related diseases containing same as active ingredient patent US11028090. 2021."},{"key":"e_1_3_5_119_1","unstructured":"Jeffrey W Ym S Maloney David J Shyh Ming Y et al. inventors. Small molecule Bromodomain inhibitors and uses therof patent US20220259200. 2022."},{"key":"e_1_3_5_120_1","unstructured":"Joseph T Carlson PW Angela SC et al. inventors. Therapeutic compounds and methods of use thereof patent US20200377474. 2020."},{"key":"e_1_3_5_121_1","unstructured":"Stefan Wd G Martin H Lucas X et al inventors. Condensed Pyrroles as Novel Bromodomain Inhibitors patent US20220055989. 2022."},{"key":"e_1_3_5_122_1","unstructured":"Jia Z Brasier Allan R Bing T et al. inventors. Inhibitors of bromodomain-containing protein 4 (BRD4) patent US11117865. 2021."},{"key":"e_1_3_5_123_1","unstructured":"Ming-Ming Z Michael O Adam V et al inventors. Cyclic Vinylogous Amides as Bromodomain Inhibitors EP3038612. 2020."},{"key":"e_1_3_5_124_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-07089-6"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2025.2463150","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,1]],"date-time":"2025-04-01T06:37:43Z","timestamp":1743489463000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2025.2463150"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,14]]},"references-count":122,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,4,3]]}},"alternative-id":["10.1080\/13543776.2025.2463150"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2025.2463150","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,14]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2024-08-02","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-31","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-02-14","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}